Boston Scientific, Ocwen Financial, Cyclacel Pharmaceuticals Stocks Moving Today

The Dow is set to extend its historic win streak. Among specific equities in focus are medical device name Boston Scientific Corporation (NYSE:BSX), mortgage company Ocwen Financial Corp (NYSE:OCN), and biotech Cyclacel Pharmaceuticals Inc (CYCC). Here's a quick look at what's moving shares of BSX, OCN, and CYCC.

Boston Scientific Drops After Lotus Valve Recall

BSX was last seen 3.3% lower at $24.33, on news the company is recalling its Lotus Valve. The stock earlier bounced off strong support at its 50-day moving average, though, and remains roughly 40% higher year-over-year. Plus, the analyst community has yet to budge. Currently, 17 of 22 brokerage firms recommend buying Boston Scientific Corporation, with no "sell" opinions to be found. 

Ocwen Financial Punished After Earnings

OCN is down 17.4% today at $4.46, and on the short-sale restricted (SSR) list, following the company's fourth-quarter earnings results. The shares are now on pace for their lowest close since early November, which is bad news for recent call buyers. Specifically, Ocwen Financial Corp has a 10-day call/put volume ratio of 11.97 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). 

Drug Fail Dooms Cyclacel Pharmaceuticals

CYCC has shed 22.1% today to trade at $4.22, on news the company's Leukemia drug, sapacitabine, failed in a late-stage study. The stock, which is also SSR, is on pace to close below the formerly supportive 80-day moving average for the first time this year. Short sellers must be cheering this development, since 13.5% of Cyclacel Pharmaceuticals Inc's available float is sold short. Going by average daily volumes, this represents 12 sessions' worth of buying power.